ClinicalTrials.Veeva

Menu

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

AstraZeneca logo

AstraZeneca

Status and phase

Enrolling
Phase 2
Phase 1

Conditions

Breast Cancer
Biliary Cancer
Ovarian Cancer
Endometrial Cancer
Bladder Cancer
Gastric Cancer
Non-small Cell Lung Cancer
Small Cell Lung Cancer Only in Module 5
Additional Indications Below for Module 4 and 5
Prostate Cancer
Cervical Cancer
Colorectal Cancer
Pancreatic Cancer

Treatments

Drug: Camizestrant
Drug: T- Dxd
Drug: AZD5305
Drug: Carboplatin
Drug: Dato-DXd
Drug: Paclitaxel

Study type

Interventional

Funder types

Industry

Identifiers

NCT04644068
2020-002688-77 (EudraCT Number)
D9720C00001

Details and patient eligibility

About

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Full description

This study is a Phase I/IIa modular, open-label, multi-center study of AZD5305 administered orally, either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies.

Enrollment

804 estimated patients

Sex

All

Ages

18 to 130 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Age ≥ 18 at the time of screening
  • Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and meeting module specific eligibility criteria..
  • Eastern Cooperative Oncology Group Performance status (ECOG PS: 0-2)
  • Life expectancy ≥ 12 weeks
  • Progressive cancer at the time of study entry
  • Patients must have evaluable disease as defined in module-specific criteria for Part A and Part B
  • Adequate organ and marrow function as defined by the protocol.
  • For Part B expansion cohorts: Provision of formalin-fixed and paraffin embedded (FFPE) tumour specimen is mandatory, where available, except if stated that it is optional in a specific Module.

For Part A:

  • Patients may have received up to one prior line of therapy with a PARPi-based regimen (either as a treatment or as maintenance)

For Part B:

  • Patients must not have received prior therapy with a PARPi-based regimen (either as a treatment or as maintenance).

Key Exclusion Criteria:

  • Treatment with any of the following:

    1. Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment
    2. Any investigational agents or study drugs from a previous clinical study within 5 half-lives or 3 weeks (whichever is shorter) of the first dose of study treatment
    3. Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks of the first dose of study treatment
    4. Any live virus or bacterial vaccine within 28 days of the first dose of study treatment
  • Concomitant use of medications or herbal supplements known to be cytochrome P450 3A4 (CYP3A4) strong and moderate inhibitors or inducers.

  • Concomitant use of drugs that are known to prolong or shorten QT and have a known risk of Torsades de Pointes.

  • Receiving continuous corticosteroids at a dose of >10 mg prednisone/day or equivalent for any reason.

  • Major surgery within 4 weeks of the first dose of study treatment.

  • Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study treatment.

  • Any history of persisting (> 2 weeks) severe pancytopenia due to any cause

  • Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of >10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded.

  • patient with known predisposition to bleeding (e.g., active peptic ulceration, recent [within 6 months] haemorrhagic stroke, proliferative diabetic retinopathy).

  • Cardiac conditions as defined by the clinical study protocol

  • Other cardiovascular diseases as defined by any of the following:

    1. Symptomatic heart failure,
    2. uncontrolled hypertension,
    3. hypertensive heart disease with significant left ventricular hypertrophy
    4. acute coronary syndrome (ACS)/acute myocardial infarction (AMI), unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 6 months.
    5. cardiomyopathy of any etiology
    6. presence of clinically significant valvular heart disease
    7. history of atrial or ventricular arrhythmia requiring treatment; subjects with atrial fibrillation and optimally controlled ventricular rate (< 100 beats per minute) are permitted.
    8. subjects with atrial fibrillation and optimally controlled ventricular rate are permitted
    9. transient ischaemic attack, or stroke within 6 months prior to screening
    10. patients with symptomatic hypotension at screening
  • Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).

  • Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305

  • Known allergy or hypersensitivity to investigational product(s) or any of the excipients of the investigational product(s).

Prior malignancy whose natural history, in the Investigator's opinion, has the potential to interfere with safety and efficacy assessments of the investigational regimen.

other module-specific criteria may apply

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

804 participants in 6 patient groups

Module 1: AZD5305 Monotherapy
Experimental group
Description:
AZD5305 Monotherapy
Treatment:
Drug: AZD5305
Module 2: AZD5305 + Paclitaxel
Experimental group
Description:
AZD5305 + Paclitaxel
Treatment:
Drug: Paclitaxel
Drug: AZD5305
Module 3: AZD5305 + Carboplatin with or without Paclitaxel
Experimental group
Description:
AZD5305 + Carboplatin with or without Paclitaxel
Treatment:
Drug: Paclitaxel
Drug: Carboplatin
Drug: AZD5305
Module 4: AZD5305 + Trastuzumab Deruxtecan
Experimental group
Description:
AZD5305 + T- DXd
Treatment:
Drug: AZD5305
Drug: T- Dxd
Module 5 AZD5305 + Datopotamab Deruxtecan
Experimental group
Description:
AZD5305 + Dato-DXd
Treatment:
Drug: Dato-DXd
Drug: AZD5305
Module 6 AZD5305 + Camizestrant
Experimental group
Description:
AZD5305 + Camizestrant
Treatment:
Drug: AZD5305
Drug: Camizestrant

Trial contacts and locations

74

Loading...

Central trial contact

AZ Breast Cancer Study Navigators; AstraZeneca Clinical Study Information Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems